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Abstract 
Introduction 
Newer antiepileptic drugs (AEDs) are increasingly prescribed; however, relatively 
limited data are available concerning their use in status epilepticus (SE) and the 
impact on outcome.  
Objectives 
To explore the evolution in prescription patterns of newer and traditional AEDs in this 
clinical setting, and their association with prognosis. 
Methods 
We analyzed our prospective adult SE registry over 10 years (2007-2016), and 
assessed the yearly use of newer and traditional AEDs and its association with 
mortality, return to baseline condition at discharge, and SE refractoriness defined as 
treatment resistance to 2 AEDs including benzodiazepines. 
Results 
In 884 SE episodes, corresponding to 719 patients, prescription of at least a newer 
AEDs increased from 0.38 per SE episode in 2007 to 1.24 per SE episode in 2016 
(mostly due to levetiracetam and lacosamide). Traditional AEDs (excluding 
benzodiazepines) declined over time from 0.74 in 2007 to 0.41 in 2016, correlating 
with the decreasing use of phenytoin. Prescription of newer AEDs was independently 
associated to a lower chance of return to baseline conditions at discharge (OR 0.58, 
95% CI 0.40-0.84), and a higher rate of SE refractoriness (OR 19.84, 95% CI 12.76-
30.84), but not with changes in mortality (OR 1.08, 95% CI: 0.58-2.00). 
Conclusion 
We observed a growing trend in newer AEDs prescription in SE over the last decade. 
However, our findings might suggest an associated increased risk of SE 
refractoriness and new disability at hospital discharge.  Pending prospective, 
comparative studies, this may justify some caution in the routine use of newer AEDs 
in SE. 
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Key findings 
- Prescription of newer antiepileptic drugs  (AED) in status epilepticus (SE) markedly 
increased during the last decade, mostly due to levetiracetam and lacosamide. 
- While mortality at hospital discharge did not significantly change, use of newer 
AEDs was independently associated with higher SE refractoriness and disability at 
discharge. 
- These findings are potentially concerning and, awaiting comparative studies, may 
justify some caution in the routine use of newer AEDs in SE. 
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Introduction 
Status epilepticus (SE) represents one of the most frequent neurological 
emergencies with significant morbidity and mortality. It thus requires prompt 
treatment in order to avoid cerebral damage, systemic complications or death(1,2). 
Current SE treatment recommendations are based on a three steps approach, with 
benzodiazepines as first-line treatment followed by intravenous antiepileptic drugs 
(AEDs); if SE termination is not achieved despite the first two lines, general 
anesthesia and coma induction may be necessary(1–4). 
 
AEDs are a heterogeneous group of medications with a variety of pharmacokinetic 
and pharmacodynamic effects. Over the past two decades, a rapid expansion in the 
number and type of AEDs has been witnessed, including several with intravenous 
formulations. AEDs are commonly divided into newer and traditional ones, according 
to the year of marketing (before or after 1990). In the treatment of epilepsy, newer 
compounds generally exhibit better tolerability and lower drug interaction with 
comparable efficacy to traditional AEDs(5); accordingly, a growing trend in the use of 
newer AEDs is being reported, although indications other than epilepsy seem to also 
contribute (6–10).  
 
Several studies already analyzed the efficacy of newer AEDs in SE(11–20); however, 
besides a previous preliminary analysis by our group(20), little is known regarding the 
evolution over time in AEDs prescription patterns in SE, and its impact on clinical 
outcome. The aims of this study were to explore the changes in prescription of newer 
and traditional AEDs in SE treatment over the last decade, and their association with 
prognosis. 
 
Methods 
In this cohort study, we retrospectively analyzed our prospective SE registry 
recording data on adults with SE episodes treated in our hospital; details have been 
described elsewhere(21,22). Briefly, SE was defined as continuous or repetitive 
seizures without full recovery in between, lasting more than 30 minutes (until 2008) 
and more that 5 minutes (since 2008)(23). All patients were identified by the 
neurological consulting team and the staff of the epilepsy/EEG unit. Children under 
16 years old and subjects with post-anoxic SE were not included. SE treatment 
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guidelines of our hospital foresee as first line a slow bolus of intravenous clonazepam 
0.015mg/kg, midazolam 0.15mg/kg (which can also be given intramuscularly), or 
lorazepam 0.1mg/kg; and as second line, intravenous levetiracetam 30 mg/kg, 
valproate 30mg/kg or phenytoin 20mg/kg. 
 
We retrieved data of SE episodes between January 1st 2007 (the first entire year 
after beginning of the registry) and December 31st 2016, a period encompassing the 
introduction in Switzerland of several newer intravenous AEDs, such as 
levetiracetam (2008) and lacosamide (2009). These included demographics, etiology 
defined as “potentially fatal” if potentially leading to death independently of SE 
treatment(24), the validated STESS severity score (relying on age, history of 
seizures, seizures type, and extent of consciousness impairment before 
treatment)(25), type and number of AED prescribed, coma induction for SE 
treatment, SE refractoriness (defined as need of more than two treatment lines) and 
outcome at hospital discharge. The latter was categorized as return to baseline 
clinical conditions, new handicap, or death(21).  
 
AEDs were divided in two groups according to the year of marketing (before or after 
1990): benzodiazepines, phenobarbital, phenytoin, valproic acid, and carbamazepine 
were considered “traditional AEDs”. Levetiracetam, pregabalin, gabapentin, 
lamotrigine, lacosamide, topiramate, felbamate, retigabine, oxcarbazepine, 
rufinamide, perampanel and brivaracetam (used off label in our hospital at the end of 
2016, as it was introduced in Switzerland in january 2017) were considered “newer 
AEDs”. Propofol, thiopental, steroids, ketamine, etomidate, ketogenic diet, 
emergency surgery, or lack of treatment (spontaneous resolution of the SE episode) 
were considered separately.  
 
The evolution of use of traditional (including and excluding benzodiazepines, which 
represent alone the first treatment line and were thus supposed to be consistently 
prescribed over time) and newer AEDs was reported as the yearly ratio between the 
total number of prescribed AEDs belonging to a given group (traditional versus 
newer), and the number of SE events. Of note, more than one newer or traditional 
AED could be used in a given episode. Frequencies of prescription of individual 
AEDs were then reported as percentage of the SE episodes for each year.  
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Statistical analysis was performed using Stata version 14 (College Station, TX, USA). 
To test associations with clinical outcome, univariable analyses over the whole study 
period were performed with Student t test and Chi2 tests as needed; stepwise 
multivariable logistic regressions were used to identify variables independently 
associated with mortality (considering patients and not episodes), return to baseline 
condition and refractory SE. Goodness of fit was assessed with a Hosmer-Lemeshow 
test. 
 
Results 
We recorded 884 SE episodes during the 10 years study period, occurring in 719 
patients. Clinical characteristics are shown in Table 1. The yearly incidence of SE 
markedly increased during the studied time lapse (from 58 episodes in 2007 to 86 in 
2016), while the proportions of patients with history of previous seizures or potentially 
fatal etiologies, as well as the proportion of SE semiological types (data not shown), 
remained globally stable.  
 
Over the entire study period, traditional AEDs were prescribed 1382 times and newer 
AEDs 767 times. As shown in Figure 1, the frequency of newer AEDs use gradually 
increased, whereas traditional AEDs utilization remained stable over time as a whole, 
but decreased if excluding benzodiazepines. Globally, newer AEDs were prescribed 
per SE episode from 0.38 in 2007 to 1.24 in 2016; conversely, traditional AEDs 
without benzodiazepines decreased from 0.74 in 2007 to 0.41 in 2016.  
 
Frequencies of use of individual AED, used in at least 10% of episodes in one year, 
are shown in Figure 2. Among traditional AEDs, phenytoin showed the most obvious 
decrease, while prescription of valproate and, less frequently, phenobarbital 
remained relatively constant. Carbamazepine was used very rarely (8 times). The 
prescription pattern of benzodiazepines also showed some evolution: clonazepam 
was most frequently and constantly administered. Lorazepam, diazepam, clobazam 
and oxazepam were administered uncommonly; their frequencies slightly declined. 
However, the use of midazolam increased as first line agent from 0% in 2007 to 15% 
in 2016, and as third line compound from 0% in 2007 to 9% in 2016. 
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Among newer AEDs, levetiracetam and lacosamide showed the major increment. In 
2007 levetiracetam was used in only 30%, but from 2010, two years after introduction 
of its intravenous formulation in Switzerland, it was prescribed in more than 50% of 
SE episodes. Intravenous lacosamide was introduced together with the oral form in 
2009 in Switzerland; since 2010 its utilization gradually increased: it was prescribed 
in nearly 40% of episodes in 2016. Even if less frequently prescribed, pregabalin also 
slightly increased. The use of oxcarbazepine, gabapentin, lamotrigine, topiramate, 
felbamate, retigabine, rufinamide, perampanel, and brivaracetam was almost 
negligible (respectively 3; 3; 9; 13; and 1 cases over the study period).  
 
Among other treatments (Figure 3), propofol increased (6.9%, N=4/58 in 2007 vs 
22.1%, N=19/86 in 2016). Further therapeutic approaches, such as thiopental, 
steroids, ketamine, ketogenic diet, surgery, and etomidate remained extremely rare 
(respectively 12; 14; 6; 3; 2; 1 cases over the study period). Finally, 1-4 patients per 
year did not receive any treatment, as their SE episode resolved spontaneously.  
 
The number of refractory SE gradually increased through time (Figure 3) with an 
average of 2.17 ± 1.98 AEDs prescribed per SE in 2007 and 2.98 ± 1.5 in 2016. The 
mean STESS score slightly increased from 2.5 ± 1.2 in 2007 to 2.7 ± 1.5 in 2016. 
Need for intubation also gradually increased: in 2007 10% of patients received coma 
and were mechanically ventilated for SE treatment, whereas in 2016 this approach 
was used in 22% of SE episodes. Outcome at discharge tended to evolve towards a 
smaller proportion of return to baseline clinical conditions; mortality remained stable 
(Figure 4).  
 
In univariate analyses, potentially fatal etiology, higher STESS score, intubation for 
SE treatment, SE refractoriness to the first two treatment lines, and newer AEDs 
prescription correlated with poorer prognosis, whereas higher STESS score, 
potentially fatal etiology, and newer AEDs were associated with refractory SE. Table 
2 illustrates the results of uni- and multivariable analyses, adjusted for recognized 
outcome predictors, especially SE severity (STESS) and etiology. Prescription of 
newer AEDs was independently correlated to a higher proportion of disability at 
discharge and a higher rate of treatment failures, but not with increased mortality. 
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These three models showed acceptable goodness of fit (P=0.33 regarding mortality, 
0.19 for return to baseline condition and 0.45 regarding refractoriness). 
 
Discussion 
During the 10 years under study, the overall prescription of newer AEDs showed an 
important increase that was inversely correlated to that of traditional AEDs (excluding 
benzodiazepines). While mortality at hospital discharge did not change significantly, 
use of newer AEDs was independently associated with higher SE refractoriness and 
disability at discharge. 
 
A similar trend of increasing prescription of newer compounds has already been 
described not only in SE, but more generally in patients with epilepsy and in the 
general population(6–10,20). In the present study, this increase was mainly due to 
levetiracetam and lacosamide. Only two years after the introduction of intravenous 
levetiracetam in Switzerland, this became the most frequently used AED in SE in our 
center, after benzodiazepines. This abrupt raise could be at least in part explained by 
the previous existence of the oral form: physicians may have been already familiar 
with this agent, generating a shorter adaptation time. Lacosamide became the 
second most frequently prescribed AED since 2015, four years after its marketing. 
 
Regarding traditional AEDs, changes in phenytoin prescription accounted mostly for 
the observed reduction, whereas VPA utilization remained globally stable. The 
potential side effects of PHT together with the relatively difficult clinical administration 
(implying cardiac monitoring) and clinical follow-up (difficult pharmacokinetics and 
challenging pharmacokinetic interactions) could explain its decrease to the benefit of 
newer compounds with better tolerability, easier administration, and supposed similar 
efficacy (17,26). 
 
Prescription of newer AEDs was associated with higher disability at hospital 
discharge after adjustment for SE severity assessed through the STESS score, SE 
etiology, intubation for SE treatment and, importantly, SE refractoriness. This result 
differs from previous assessments suggesting a comparable efficacy of newer 
compounds in patients with epilepsy(17,19,27–30). In those studies, the vast majority 
of patients had generalized convulsive SE, thus possibly limiting generalizability to 
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patients, like in the present cohort, including all SE types.  A previous study from our 
group, restricted to the years 2006-2010, reported similar findings as compared to 
the present study(20), with a greater likelihood to receive newer AEDs in patients 
with more aggressive SE forms (stratified by potentially fatal etiology, higher STESS, 
or refractory SE). Indeed, as newer AEDs present fewer cardio-respiratory side 
effects, a low potential for interactions and linear pharmacokinetics properties, they 
could be prescribed preferentially in patients with co-medications and significant co-
morbidities (“confounding by indication”). Nevertheless, our multivariable analysis 
was adjusted for important outcome predictors including SE and etiology severities, 
total number of prescribed AED, and SE refractoriness.  
 
Finally, the number of our SE episodes almost doubled between 2007 and 2016, 
possibly due to the increase of EEG monitoring in the last years(31) and the 
detection of more aggressive SE forms in patients with altered consciousness(32). Of 
note, the breakdown into the different SE semiological types did not change 
significantly between 2007 and 2016. Nevertheless, patients treated with newer 
AEDs showed a higher rate of refractoriness even after correction for STESS score 
and etiology. This could suggest a lower efficacy of newer compounds. A potential 
explanation could be that newer AEDs can be administered faster than phenytoin, 
thus shortening the time during which the clinical response is assessed. This, in turn, 
might induce clinicians to consider treatment escalation quicker than previously. The 
increase of the proportion of patients with new handicap at discharge seems however 
to contradict this possibility. In line with this consideration, a recent randomized 
controlled trial did not disclose any benefit regarding generalized convulsive SE 
control after addition of levetiracetam to clonazepam(33).  
 
Levetiracetam was by far the most frequent newer AED. Various studies, including a 
meta-analysis, comparing it with phenytoin or valproate, showed no difference in 
terms of clinical seizures cessation(17,19). However analysis from our group 
described a higher rate of treatment failures with levetiracetam than valproate(18). 
This may reflect a suboptimal SE treatment approach with insufficient doses of newer 
AEDs, or their prescriptions without or with underdosed benzodiazepines as first line 
treatment(34). However, in animal studies levetiracetam has shown a relatively slow 
penetration into the central nervous system, with latencies of more than 1 hour to 
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achieve maximum concentrations in the cerebrospinal or in the brain extra-cerebral 
fluid(35–37). Animal studies with phenytoin, on the other side, shows maximum 
concentrations in cerebrospinal and brain extra-cerebral fluids within 9-13minutes 
and 39-34minutes, respectively(38). This could possibly correlate with a slower 
clinical action of LEV and explain at least partially the relationship between 
refractoriness and newer AEDs. 
 
Our study is to the best of our knowledge the fist analyzing prescription patterns of 
AEDs in SE over a long time period in a large and well characterized adult cohort. 
The SE registry being prospectively filled by the same investigators, its internal 
validity appears robust. We nevertheless acknowledge limitations. We assessed only 
prescription of AEDs, without information about treatment side effects. We aimed at 
describing the evolution trends of AED use in the era of newer compounds, but not at 
analyzing the impact of each single medication.  A selection bias may be present, as 
we considered only patients from a university hospital; however, in our country the 
vast majority of SE patients are treated in larger hospitals. Due to retrospective data 
analysis, some confounding factors might have been at play: we used multivariable 
analyses to adjust for the most important known outcome predictors. However, 
adequacy of first line treatment, adherence to guidelines and SE duration were not 
assessed. Nevertheless, a previous study from our group reported no major effect of 
treatment adherence to guidelines on prognosis, after considerations of robust 
outcome predictors (etiology, STESS score) over a more restricted time lapse(39). It 
seems also unlikely that the poorer outcome found in patients treated with newer 
AEDs could be explained by a systematic difference in treatment appropriateness 
between the two groups. Outcome was scored at hospital discharge: an information 
bias may have been at play regarding newer handicap, which evolves over time. 
While a systematic bias seems unlikely, we underscore that mortality, being a robust 
variable, did not correlate with newer AEDs prescription. In any case, these 
considerations do not apply to SE refractoriness. SE timing definition changed in 
2008; however, we extrapolate that this may have lead to miss at most only 7 
episodes lasting less than 30 minutes in 2007 (corresponding to less than 1% of the 
total number). Finally, due to the study design, the described associations are not 
necessarily reflecting causality. 
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Conclusion 
A growing trend in newer AEDs prescription in SE was observed over the last 
decade. However, our findings do not show a resulting prognosis improvement; 
rather, they seem to suggest an association with increased new disability at 
discharge and SE refractoriness. These findings are potentially concerning, and call 
for some caution in the indiscriminate use of newer AEDs in SE: the ongoing ESETT 
trial(40) may help elucidating this issue.  
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Table 1. Clinical characteristics of the study population 
Year 
SE 
episodes 
(n) 
Women 
(%) 
Age (mean 
+/-SD) 
Potentially 
fatal 
etiology 
(%) 
History of 
previous 
seizure 
(%) 
STESS 
score 
(mean ± 
SD) 
2007 58 46.6 60.1±  18.1 48.3 48.3 2.5 ± 1.3 
2008 79 67.1 59.5 ±  16.6 45.6 48.1 2.4 ± 1.5 
2009 80 48.8 58.7 ±  19.8 37.5 60 2.3 ± 1.5 
2010 93 47.3 62.9 ±  18.7 44.1 43 2.7 ± 1.3 
2011 93 48.4 65.3 ±  17.0 53.8 53.8 2.7 ± 1.4 
2012 93 45.2 60.8 ±  16.3 51.6 59.1 2.4 ± 1.6 
2013 99 48.5 57.8 ±  20.3 41.4 50.5 2.7 ± 1.5 
2014 88 45.5 58.3 ±  22.3 47.7 61.4 2.3 ± 1.6 
2015 115 54.8 65.8 ±  16.2 53.1 42.6 3.2 ± 1.5 
2016 86 44.2 59.9 ± 16.0  54.7 56.9 3.0 ± 1.5 
2007-2016 884 48.8 61.1 ± 18.6 47.9 52.1 2.6 ± 1.5 
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Table 2. Variables of interest as compared to prognosis (mortality and new handicap) and 
Status epilepticus refractoriness (resistance to two treatment lines) 
  Dead Alive p univariate p multivariate OR 95% CI 
N (patients) 106 613         
Gender: women (%) 53.8 42.2 0.147  -     
Potentially fatal 
etiology (%) 76.4 46.2 <0.001 <0.001 3.63 2.18-6.03 
STESS (mean ±SD) 3.42 ± 1.24 2.58 ± 1.5 <0.001 <0.001 1.38 1.17-1.61 
Intubation (%) 19.8 10.4 0.006 0.605 1.18 0.63-2.23 
Refractory SE (%) 67.0 40.6 <0.001 <0.001 3.05 1.67-5.58 
 AEDs/episodes 
(mean ±SD) 3.28  ± 1.57 2.40 ± 1.3 < 0.001  -     
Use of newer AED 
(%) 79.2 61.7 <0.001 0.738 0.89 0.47-1.71 
  
Return to 
baseline 
New 
handicap 
or death p univariate p multivariate OR 95% CI 
N (episodes) 453 431         
Gender: women (%) 45.7 52.0 0.062 -      
Potentially fatal 
etiology (%) 34.4 62.2 <0.001 <0.001 0.35 0.25-4.79 
STESS (mean ±SD) 2.20 ± 1.43 3.04 ± 1.44 <0.001 <0.001 0.7 0.63-0.78 
Intubation (%) 6.2 17.6 <0.001 0.287 0.71 0.37-1.34 
Refractory SE (%) 28.9 57.3 <0.001 0.562 0.85 0.50-1.45 
AEDs/episodes 
(mean ±SD) 2.13 ± 1.2 3.00 ± 1.6 <0.001 0.014 0.75 0.59-0.94 
Use of newer AED 
(%) 49.2 76.8 <0.001 0.006 0.58 0.39-0.86 
  Refractory 
Non 
refractory p univariate p multivariate OR 95% CI 
N (episodes) 378 506         
Gender: women (%) 47.1 50.0 0.39 -      
Potentially fatal 
etiology (%) 53.7 43.7 0.003 0.611 0.91 0.65-1.23 
STESS (mean ±SD) 2.86 ± 1.55 2.42 ± 1.4 <0.001 0.008 1.17 1.04-1.31 
Use of newer AED 
(%) 93.1 39.9 <0.001 <0.001 20.42 12.79-32.60 
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Figure legends 
 
Figure 1:  
Evolution of the prescription pattern of newer AEDs, traditional AEDs and traditional 
AEDs with exclusion of benzodiazepines. Results are expressed the yearly ratio 
between the total number of AEDs prescribed in a given group and the number of SE 
events.  
AEDs : antiepileptic drugs. SE : status epilepticus. LEV : levetiracetam. LCM : lacosamide  
 
Figure 2: 
Use of individual AEDs through time. Results are expressed as percentage of the SE 
episodes for each year.  
AEDs : antiepileptic drugs. SE : status epilepticus. LEV : levetiracetam. CLZ : clonazepam. MDZ : 
midazolam. PHT : phenytoin. VPA : valproate. LCM : lacosamide. PGB : pregabalin 
 
Figure 3: 
Evolution of mean STESS, refractory SE and intubation for treatment. Results are 
expressed as percentage of the SE episodes for each year or mean. 
AEDs : antiepileptic drugs. SE : Status epilepticus . PRO : propofol. STESS: Status epilepticus 
severity score. THP : thiopental.  
 
Figure 4 : 
Evolution of outcome. Results are expressed as percentage of SE episodes for each 
year. 
SE : Status epilepticus .  
 
 
Fig 1. Evolution of the prescription pattern of newer AEDs, traditional AEDs and 
traditional AEDs with exclusion of benzodiazepines. Results are expressed the 
yearly ratio between the total number of AEDs prescribed in a given group and 
the number of SE events.
AEDs : antiepileptic drugs. SE : status epilepticus. LEV : levetiracetam. LCM : lacosamide 
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Fig 2. Use of individual AEDs through time. Results are expressed as percentage of 
the SE episodes for each year. 
AEDs : antiepileptic drugs. SE : status epilepticus. LEV : levetiracetam. CLZ : clonazepam. 
MDZ : midazolam. PHT : phenytoin. VPA : valproate. LCM : lacosamide. PGB : pregabaline.
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Fig 3. Evolution of mean STESS, refractory SE and intubation for treatment. 
Results are expressed as percentage of the SE episodes for each year or 
mean.
AEDs : antiepileptic drugs. SE : Status epilepticus . PRO : propofol. STESS: Status 
epilepticus severity score. THP : thiopental.
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Fig 4. Evolution of outcome. Results are expressed as percentage of SE 
episodes for each year.
SE : Status epilepticus . 
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